Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02878083
- Locations
- 🇫🇷
Chu Angers, Angers, France
🇫🇷Chd Vendee, La Roche Sur Yon, France
🇫🇷Chu Nantes, Nantes, France
Reduce Risk for Crohn's Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- PIBD-Net
- Target Recruit Count
- 312
- Registration Number
- NCT02852694
- Locations
- 🇫🇷
Hôpital Necker -Enfants Malades (Service de gastro-enterologie), Paris, France
Treatment Tapering in JIA With Inactive Disease
- Conditions
- Interventions
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 62
- Registration Number
- NCT02840175
- Locations
- 🇫🇷
Necker Children's Hospital, Paris, France
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
- Conditions
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 578
- Registration Number
- NCT02833350
- Locations
- 🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇺🇸Medvin Clinical Research, Covina, California, United States
🇺🇸TriWest Research Associates, LLC, El Cajon, California, United States
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 206
- Registration Number
- NCT02808975
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center /ID# 168438, Boston, Massachusetts, United States
🇧🇪UZ Gent /ID# 150906, Gent, Oost-Vlaanderen, Belgium
🇨🇦NewLab Clinical Research Inc. /ID# 151315, St. John's, Newfoundland and Labrador, Canada
Triple Combination Therapy in High Risk Crohn's Disease (CD)
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 55
- Registration Number
- NCT02764762
- Locations
- 🇺🇸
Cotton O'Neil Clinical Research, Topeka, Kansas, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇨🇦PerCuro Clinical Research Ltd, Victoria, British Columbia, Canada
Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- American University of Beirut Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT02706704
- Locations
- 🇱🇧
American University of Beirut Medical Center, Beirut, Lebanon
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 341
- Registration Number
- NCT02696785
- Locations
- 🇺🇸
Klein and Associates MD, PA, Hagerstown, Maryland, United States
🇺🇸Marietta Rheumatology, Marietta, Georgia, United States
🇺🇸Sarasota Arthritis Center, Sarasota, Florida, United States
Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- University of Helsinki
- Target Recruit Count
- 60
- Registration Number
- NCT02634541
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇫🇮Päijät-Häme Central Hospital, Lahti, Finland
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2015-12-14
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1629
- Registration Number
- NCT02629159
- Locations
- 🇺🇸
Precision Research Org, LLC /ID# 143092, Miami Lakes, Florida, United States
🇺🇸DM Clinical Research /ID# 151357, Tomball, Texas, United States
🇿🇦Arthritis Clinical Research Tr /ID# 144874, Cape Town, Western Cape, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.